Arun P. Wiita, MD, PhD

Blockade of the HSP70-BAG3 chaperone/co-chaperone interaction to overcome proteasome inhibitor-refractory multiple myeloma

Multiple myeloma still has no cure. Many patients benefit from drugs called proteasome inhibitors, but unfortunately almost all cancers eventually become resistant. Here, we investigate the potential of a new class of drugs, called HSP70-BAG3 inhibitors, to specifically target resistant myeloma leading to deeper remissions and longer survival for patients.